DBV Technologies (NASDAQ:DBVT) Shares Gap Down – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT) gapped down before the market opened on Wednesday . The stock had previously closed at $23.80, but opened at $22.32. DBV Technologies shares last traded at $22.0710, with a volume of 54,863 shares.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Citizens Jmp lifted their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research report on Wednesday, December 17th. Guggenheim reiterated a “buy” rating and set a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Sunday. Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a report on Wednesday, December 17th. Finally, Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Price Performance

The business has a 50 day simple moving average of $19.76 and a 200 day simple moving average of $14.65. The stock has a market cap of $903.40 million, a PE ratio of -4.36 and a beta of -0.98.

Insider Buying and Selling

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 3,369,627 shares of company stock valued at $15,489,908 in the last 90 days. Corporate insiders own 1.44% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies in the 2nd quarter valued at $340,000. Vivo Capital LLC acquired a new stake in shares of DBV Technologies in the second quarter worth about $9,659,000. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies during the 2nd quarter valued at about $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies during the 2nd quarter valued at about $9,659,000. Finally, Octagon Capital Advisors LP bought a new position in shares of DBV Technologies in the 2nd quarter valued at approximately $9,315,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.